These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 1355463)

  • 1. c-erbB-2 oncogene in breast cancer: the right target or a decoy?
    Anderson TJ
    Hum Pathol; 1992 Sep; 23(9):971-3. PubMed ID: 1355463
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunohistochemical distribution of c-erbB-2 in infiltrating and in situ breast cancer.
    Gusterson BA; Machin LG; Gullick WJ; Gibbs NM; Powles TJ; Price P; McKinna A; Harrison S
    Int J Cancer; 1988 Dec; 42(6):842-5. PubMed ID: 2903851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phases of mammary cancer.
    Iglehart JD; Kerns BJ; Huper G; Marks JR
    Breast Cancer Res Treat; 1995 Jun; 34(3):253-63. PubMed ID: 7579490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of c-erbB-2 in in situ and in adjacent invasive ductal adenocarcinomas of the female breast.
    Maguire HC; Hellman ME; Greene MI; Yeh I
    Pathobiology; 1992; 60(3):117-21. PubMed ID: 1352687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [C-erbB-2 oncogene amplification in breast cancer in correlation to steroid and epidermal growth factor receptor].
    Manavi M; Czerwenka KF; Zeillinger R; Speiser P; Kury F; Steinhart U; Peschke M; Kubista E; Reinold E
    Zentralbl Gynakol; 1992; 114(2):82-5. PubMed ID: 1350129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
    Ottesen GL
    APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.
    Allred DC; Clark GM; Molina R; Tandon AK; Schnitt SJ; Gilchrist KW; Osborne CK; Tormey DC; McGuire WL
    Hum Pathol; 1992 Sep; 23(9):974-9. PubMed ID: 1355464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma.
    Somerville JE; Clarke LA; Biggart JD
    J Clin Pathol; 1992 Jan; 45(1):16-20. PubMed ID: 1346789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotein.
    Poller DN; Snead DR; Roberts EC; Galea M; Bell JA; Gilmour A; Elston CW; Blamey RW; Ellis IO
    Br J Cancer; 1993 Jul; 68(1):156-61. PubMed ID: 8100443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-erbB-2 oncogene protein in in situ and invasive lobular breast neoplasia.
    Porter PL; Garcia R; Moe R; Corwin DJ; Gown AM
    Cancer; 1991 Jul; 68(2):331-4. PubMed ID: 1676930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 protein expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein.
    Poller DN; Roberts EC; Bell JA; Elston CW; Blamey RW; Ellis IO
    Hum Pathol; 1993 May; 24(5):463-8. PubMed ID: 8098318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. erbB2 expression in breast and other human tumours.
    Wright C; Prasad K; Lennard TJ
    J Clin Pathol; 1992 May; 45(5):459-60. PubMed ID: 1350790
    [No Abstract]   [Full Text] [Related]  

  • 13. [Use of polymerase chain reaction (PCR) as an additional diagnostic method in gynecologic oncology].
    Czerwenka KF; Zeillinger R; Kury F; Manavi M; Speiser P; Peschke M; Steinhart U; Hosmann JW; Kubista E
    Gynakol Rundsch; 1991; 31 Suppl 2():378-9. PubMed ID: 1686430
    [No Abstract]   [Full Text] [Related]  

  • 14. Induction of epithelial abnormalities that resemble human breast lesions by the expression of the neu/erbB-2 oncogene in reconstituted mouse mammary gland.
    Bradbury JM; Arno J; Edwards PA
    Oncogene; 1993 Jun; 8(6):1551-8. PubMed ID: 8099220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 mutations and c-erbB-2 amplification in intraductal and invasive breast carcinomas of high histologic grade.
    Tsuda H; Iwaya K; Fukutomi T; Hirohashi S
    Jpn J Cancer Res; 1993 Apr; 84(4):394-401. PubMed ID: 8099903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast.
    Liu E; Thor A; He M; Barcos M; Ljung BM; Benz C
    Oncogene; 1992 May; 7(5):1027-32. PubMed ID: 1349163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen receptor, c-erbB-2 and nm23/NDP kinase expression in the intraductal and invasive components of human breast cancers.
    Kobayashi S; Iwase H; Itoh Y; Fukuoka H; Yamashita H; Kuzushima T; Iwata H; Masaoka A; Kimura N
    Jpn J Cancer Res; 1992 Aug; 83(8):859-65. PubMed ID: 1356959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The diagnosis and management of pre-invasive breast disease: promise of new technologies in understanding pre-invasive breast lesions.
    Jeffrey SS; Pollack JR
    Breast Cancer Res; 2003; 5(6):320-8. PubMed ID: 14580250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast.
    Lodato RF; Maguire HC; Greene MI; Weiner DB; LiVolsi VA
    Mod Pathol; 1990 Jul; 3(4):449-54. PubMed ID: 2170971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.
    van de Vijver MJ; Peterse JL; Mooi WJ; Wisman P; Lomans J; Dalesio O; Nusse R
    N Engl J Med; 1988 Nov; 319(19):1239-45. PubMed ID: 2903446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.